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a b s t r a c t
Non-myeloablative allogeneic transplant (NMAT) has a curative potential for patients who are not
myeloablative allogeneic transplant (MAT) candidates. We report a phase II trial of a NMAT regimen with
cyclophosphamide and ﬂudarabine in 40 patients; 21 of whom had a prior MAT. Day þ100 and 1-year
transplant-related mortality (TRM) post-NMAT were 13% and 34%, respectively. Day þ100 and 1-year
Overall/Progression-Free Survival (OS/PFS) were 80%/65% and 43%/25%, respectively. OS was higher in
patients with KPSZ90 and lower in recipient/donor CMVþ/ vs. other combinations. FluCy has low
TRM and is curative in about 20% of high-risk patients.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
NMAT has emerged over the last 2 decades as a promising
alternative with reduced TRM for patients who would otherwise
not be eligible for MAT. Aggressive disease poses a challenge,
while patients in complete remission (CR) at the time of transplant
can beneﬁt from NMAT [1,2]. We summarize our prospective
phase II clinical trial of ﬂudarabine and cyclophosphamide for
NMAT, with a focus on evaluating the efﬁcacy of NMAT in patients
with high-risk/aggressive disease.
2. Methods
This prospective IRB-approved phase II trial enrolled 40
patients from 4/2002 to 12/2008 with hematologic diseases.
Eligibility included: age 4–75 years; HLA-suitable donor, KPSZ50,
adequate organ function, no uncontrolled co-morbidity or infec-
tion, and ineligible for MAT.
2.1. Conditioning regimen and GvHD prophylaxis
Starting on day 5, ﬂudarabine 25 mg/m2/d (actual body
weight)5 doses and cyclophosphamide 50 mg/kg/d IV2 doses
(lesser of ideal or adjusted body weight) were given. For graft-
versus-host disease (GVHD) prophylaxis, patients received metho-
trexate 5 mg/m2 on day þ1, þ3, and þ6, mycophenolate mofetil
day 1 to þ60, and tacrolimus starting day 1.
2.2. Cell dose and neutrophil recovery
Peripheral blood grafts had a minimum total cell dose of
2106 CD34þcells/kg. Marrow grafts had a minimum of 1108
nucleated cells/kg. Absolute neutrophil count (ANC)4500/μL for
three consecutive days deﬁned engraftment. Failure to engraft was
no ANC recovery by day þ45 post-NMAT. Platelet engraftment
was deﬁned as 420,000/mm3 after 7 days with no platelet
transfusions.
2.3. Response evaluations
Disease response was measured on or before Day þ100. The
Center for International Blood and Marrow Transplant Registry
(CIBMTR) criteria deﬁned remission, relapse and progression.
Disease status pre-NMAT was deﬁned using CIBMTR deﬁnitions
of low, intermediate and high risk [3].
2.4. Statistical analyses
Sample size and power calculations were based on the primary
endpoint: Day þ100 TRM, deﬁned as death due to any cause
except underlying disease. The null hypothesis was Day þ100
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TRM¼25%. A two-stage study design was used with early stopping
rules for patient safety. The decision rules yielded a type I error
rate¼0.0933 and power¼0.8709. Po0.05 was considered statis-
tically signiﬁcant, with PZ0.05–0.09 considered a trend.
Secondary outcomes included OS, PFS and toxicity. Survival was
updated through November 2012. The Kaplan–Meier method was
used to construct survival curves, and the log rank test was used to
determine statistical signiﬁcance. OS was measured from day 0
(HCT infusion) to death due to any cause or last follow-up (censor).
PFS was calculated from day 0 until date of last follow-up (censor),
or documented relapse/progression/death (events). SPSSs version
21software was used for data analysis (IBM Corp., Armonk, NY).
3. Results
Patient characteristics are summarized in Table 1. Siblings were
HLA-matched (N¼14) or 1-Ag mismatched (N¼1). Unrelated donors
were HLA-matched (N¼14) or 1-2 antigen HLA-mismatched (N¼11).
Median time to ANC recovery was 14 days (range 10–21); 3 died
before neutrophil engraftment (Day þ15, 27, 32) and there were no
secondary graft failures. Median time to platelet recovery was 27
days (range 9–120); 7 patients did not nadir below 20,000/mm3.
3.1. Treatment related mortality (TRM)
The observed cumulative incidence of TRM at Day þ100 was
statistically signiﬁcantly lower than expected at 12.6% (95% CI
2–23%, P¼0.03). The causes of Day þ100 TRM were infection
(n¼4) and regimen-related toxicity (n¼1).
3.2. Infections
Viral infections post-HCT were documented in 44% of patients
(n¼18). Fungal infections were documented in 17% of patients.
Two patients died of bacterial sepsis before engraftment (Day
þ15, 27).
3.3. GvHD
Cumulative incidence of Grades II–IV acute GvHD by Day þ100
was 35% (95% CI 20–51%). Cumulative incidence of extensive
chronic GvHD at 1-year was 64% (95% CI 45–83%).
3.4. Overall Survival (OS)
The median follow-up was 5 years (range 2–8 years). Day þ100
OS was 80% (95% CI 68–92%); 1 year OS was 43% (95% CI 27–58%);
3 year OS was 19% (CI 7–31%).
The univariate analysis of factors associated with OS is in
Table 2. Three pre-NMAT variables, recipient/donor CMV serolo-
gical status, KPS and disease status were signiﬁcantly associated
with OS (Table 2, Figs. 1a and b), whereas age and donor relation/
HLA match were not (Table 2, Fig. 1c).
3.5. Progression free survival (PFS)
By Day þ100, 21 (54%) patients achieved a complete remission
(half of these later relapsed), 5 (12%) had a partial response (2 died
of disease, 3 received other therapy and are all alive 44 years
post-NMAT), 2 (5%) had stable disease (both later progressed and
died 9 months and 3.8 years post-NMAT), 8 (20%) had progressed
(all of whom died 3–38 days later), and 4 (10%) were not evaluable
due to early TRM. Day þ100 PFS was 64% (CI 49–78%); 1-year PFS
was 27% (CI 13–40%); 3-year PFS was 17% (CI 5–28%). The
univariate analysis of factors associated with PFS is summarized
in Table 2, demonstrating only recipient/donor CMV serological
status as signiﬁcantly associated with PFS.
Table 1
Patient characteristics.
Variable Total N¼40
n (%)
Gender
Male 24 (60)
Female 16 (40)
Age (years)
o40 7 (18)
40–59 21 (53)
60–75 12 (30)
Diagnosis
NHL 12 (30)
AML 10 (25)
HL 8 (20)
MDS 5 (13)
MM 2 (5)
ALL 2 (5)
PLL 1 (3)
Karnofsky Performance Score
90–100 13 (33)
80 12 (30)
o80 15 (38)
Disease status at BMT
Complete remission 11 (28)
Primary induction failure/untreated 12 (30)
Relapse 17 (43)
Prior BMT
No prior BMT 19 (48)
Autologous 19 (48)
Allogeneic 2 (5)
Hematopoietic cell source
Peripheral Blood 37 (93)
Bone Marrow 3 (8)
GvHD prophylaxis
FKMMFþ/MTX 38 (95)
FKMTX 2 (5)
Donor type
Unrelated 25 (63)
Related 15 (38)
Gender matching
Matched 23 (58)
Mismatched 17 (43)
HLA match
Matched 28 (70)
Mismatched 12 (30)
Cytomegalovirus serology recipient/donor
CMVþ/þ 13 (33)
CMVþ/ 13 (33)
CMV / 10 (25)
CMV /þ 4 (10)
ABO matching
Matched 20 (50)
Major Mismatch 10 (25)
Minor Mismatch 10 (25)
Ejection fraction pre-NMAT
Z60% 23 (58)
o60% 17 (43)
CIBMTR disease risk category
High 26 (65)
Intermediate 8 (20)
Low 6 (15)
FK: tacrolimus; MTX: methotrexate; MMF: mycophenolate;
CMV: cytomegalovirus.
HLA-match for sibling donors is 6/6 or 8/8, HLA-match for
unrelated donors is 8/8 or 10/10.
HLA-mismatch for sibling donors is 7/8, HLA-mismatch for
unrelated donors is 8/10, 9/10, or 11/12.
% May not add up to 100% due to rounding.
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4. Discussion
We observed a signiﬁcantly lower than expected Day þ100
TRM. Other NMAT studies [4,5] have shown similar ﬁndings,
although 60% of our trial population had high risk disease per
the CIBMTR classiﬁcation. In this and other studies, late TRM and
disease progression remains problematic and offsets the reduction
in early TRM [6].
Outcomes of other NMAT studies may have been related to type
of disease [7] and disease burden [8] at the time of transplant,
however, our results in high-risk, advanced disease patients are
comparable to McClune et al. [9]. We demonstrate that durable
disease control can be achieved in 15% of patients who are not in
remission pre-NMAT, with a 3-year OS of 34% in patients with
relapsed disease vs. 0% in primary induction failure patients. One
retrospective analysis of MDS and AML patients found that non-
relapse mortality, 3-year OS and PFS did not vary between MAT
and NMAT [10]. Two studies have documented a stronger Graft-
versus-Leukemia (GvL) effect for those in remission vs. active
disease pre-NMAT [10,11]. A randomized multi-center trial is
currently accruing patients to compare MAT vs. NMAT regimens
in AML and MDS patients [12].
In our study, lower KPS was a signiﬁcant risk factor for shorter
OS that is comparable to 2 other studies [13,14]. This factor could
be studied further as a prospective, prognostic indicator of survival
along with the HCT co-morbidity index [15]. A major cause of
morbidity and mortality following NMAT is infection, in both our
study and others [16,17]. Despite a decrease in early bacterial
infection due to a shorter time to neutrophil recovery and less
mucosal damage, there is an increased risk for later viral and
Table 2
Univariate analysis of Progression-Free and Overall Survival.
Factor Progression-Free Survival Overall Survival
Day 100 1-Year 3-Year P Day 100 1-Year 3-Year P
Age (years) NS NS
o40 57% (20–94) 29% (0–62) 29% (0–62) 71% (38–100) 57% (20–94) 29% (0–62)
40–59 67% (47–87) 24% (6–42) 6% (0–17) 81% (64–98) 43% (22–64) 17% (0–34)
Z60 67% (40–93) 25% (0–50) 17% (0–38) 83% (62–100) 33% (7–60) 17% (0–38)
CIBMTR disease risk NS NS
Low 71% (38–100) 29% (0–62) 14% (0–40) 100% 29% (0–62) 14% (0–40)
Intermediate 89% (68–100) 33% (3–64) 22% (0–49) 89% (68–100) 67% (36–97) 33% (3–64)
High 50% (30–70) 21% (5–37) 10% (0–24) 71% (53–89) 38% (18–57) 15% (0–30)
Disease status pre-NMAT 0.075 0.025
CRZ1 82% (59–100) 36% (8–65) 18% (0–41) 100% 46% (16–75) 18% (0–41)
RelapseZ1 65% (42–87) 29% (8–51) 22% (1–43) 77% (56–97) 65% (42–87) 34% (11–57)
Never in CR 50% (22–78) 8% (0–24) 0% 67% (40–93) 8% (0–24) 0%
KPS 0.097 0.014
90–100 92% (78–100) 39% (12–65) 23% (0–46) 100% 54% (27–81) 39% (13–65)
80 58% (31–86) 25% (0–50) 17% (0–38) 83% (62–100) 58% (30–86) 17% (0–38)
o80 40% (15–65) 13% (0–31) 0% 60% (35–85) 20% (0–40) 13% (0–30)
Donor relation/HLA match NS NS
Matched related 64% (39–89) 43% (17–69) 27% (3–51) 79% (58–100) 50% (24–76) 36% (11–61)
Matched unrelated 79% (57–100) 21% (0–43) 7% (0–21) 86% (68–100) 50% (24–76) 7% (0–21)
HLA-mismatched 42% (14–70) 8% (0–24) 8% (0–24) 75% (50–100) 25% (1–50) 17% (0–38)
CMV Rþ/D 0.004 o0.001
Rþ/D 31% (6–56) 8% (0–22) 0% 69% (44–94) 8% (0–22) 0%
Other 82% (67–96) 33% (16–51) 21% (5–37) 85% (72–98) 59% (40–78) 29% (12–46)
KPS: Karnofsky Performance Score; CMV Rþ indicates recipient is serologically IgG positive pre NMAT, CMV D indicates donor is serologically IgG negative prior to stem
cell collection, NS: not statistically signiﬁcant P40.1.
Fig. 1. (a) P¼0.014; thin solid line: KPS 90–100, dashed line: KPS 80, thick solid line¼KPSo80. (b) Po0.001; dashed line: CMV Rþ/D , solid line: all other combinations.
(c) P40.5, thin solid line: HLA-matched related donor, dashed line: HLA-matched unrelated donor, thick solid line: HLA-mismatched donor.
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fungal infections [17,18]. Our study conﬁrms another [16] that
CMV serologic status is associated with OS and needs to be
considered in the donor selection process.
The development of NMAT has changed the application of
allogeneic transplantation. The curative effect of NMAT is depen-
dent on donor cell-mediated immunotherapy [19–21]. The reduc-
tion of early TRM must be balanced with PFS and late TRM. FluCy
has a low rate of early TRM and is curative in approximately 20% of
advanced disease patients. Identiﬁcation of pre-NMAT factors
which predict for long-term survival may allow more appropriate
patient selection for FluCy versus alternative NMAT regimens and
newer reduced toxicity regimens.
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